Summary:
A Research Study on CDX-0159 for Adults With Moderate-to-Severe Atopic Dermatitis. Study Type: Clinical Trial (Randomized, Double-Blind, Placebo-Controlled)
Purpose of the Study
This study is testing an investigational drug called CDX-0159 to see if it can help treat moderate-to-severe atopic dermatitis (eczema). Researchers want to find out if this drug can reduce skin inflammation, itching, and other symptoms compared to a placebo (inactive treatment).
How the Study Works
- Participants will be randomly assigned to receive CDX-0159 or a placebo.
- The drug is given as an injection at specific intervals.
- Doctors will monitor participants for changes in symptoms, side effects, and overall skin health.
- The study includes regular check-ups over several months.
Who Can Join?
- Adults (18+) diagnosed with moderate-to-severe atopic dermatitis
- Must have had symptoms for at least 6 months
- Cannot have certain other skin conditions or serious health issues
Qualified Participants May Receive:
Compensation provided for eligible candidates.